We’re proud to announce that we’ve raised an additional $55M as part of our Series B financing from a fantastic cohort of new investors Premji Invest, Lingotto, Microsoft, and The Nature Conservancy and existing investors Kinnevik, True Ventures, FPV Ventures, Level Ventures, and JAZZ Venture Partners! In recognition of this milestone, our Founder and CEO, Viswa Colluru, PhD sat down with Marina Temkin, CFA of TechCrunch to discuss the raise and how it will help us achieve our mission of translating nature into new medicines. For more, check out the Press Release, here: https://lnkd.in/ewEngcwd And Marina’s article, here: https: //https://lnkd.in/euQt_vPT
inspiring, very promising
Love that The Nature Conservancy was involved. Very cool.
Wow, that's very impressive 👏 Congrats for all the successes and future ones of Enveda!
Amazing strides.!...proud to be a #Envedian😊
Congratulations
Congratulations Viswa Colluru, PhD and Team Enveda Biosciences. Combining Natural Compounds with AI is a powerful remedy.
Congratulations Enveda Biosciences 🎉🎉🎉
Congrats enveda team! Cheering you on!
Get drug discovery and development done | Turn ideas into cures
4wRevisiting what nature has provided is a use of AI I can really get behind. Decades ago, we (drug industry) walked away from natural products research because we chose not to improve the way we tested and isolated specific small molecules. Now, we have AI powered early triage to reduce the physical workload of identification of small mol and proteins as viable therapeutics, We also have synthetic planning and execution tools we didn't have before. Hopefully Enveda Biosciences will use technology to make isolating and reproducing the molecules they find fast and cost effective. I think this is a fantastic opportunity for them to discover hundreds of therapeutics right under out noses.